Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?

The Lancet Infectious Diseases

Volumn 10, Issue 2, 2010, Pages 133-137

  Bauch, Chris T ^a   Li, Meng ^b   Chapman, Gretchen ^b   Galvani, Alison P ^c  

^a UNIVERSITY OF GUELPH   (Canada)

^b RUTGERS UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MATHEMATICAL MODEL; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; UNCERTAINTY; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION;

EID: 74849130005     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70004-9     Document Type: Note

References (32)

1. Schmiedeskamp M., and Kockler D. Human papillomavirus vaccines. Ann Pharmacother 40 (2006) 1344-1352
2. Clifford G., Francheschi S., Diaz M., Munoz N., and Villa L.L. Chatper 3: HPV type distribution in women with and without cervical neoplastic diseases. Vaccine 24 suppl 3 (2006) S26-S34
3. Wright T., and Goldie S.J. Screening for cervical cancer. Science 290 (2000) 1651
4. Goldie S.J., Kim J.J., and Myers E.R. Cost-effectiveness of cervical cancer screening. Vaccine 24 suppl 3 (2006) S164-S170
5. Naucler P., Ryd W., Toernberg S., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Eng J Med 357 (2007) 1589-1597
6. Mayrand M., Duarte-Franco E., Rodrigues I., et al. Human papilloamvirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
7. Sterman J. Learning from evidence in a complex world. Am J Public Health 96 (2006) 505-514
8. Goldie S.J., Grima D., Kohli M., Wright T.C., Weinstein M., and Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 106 (2003) 896-904
9. Garnett G.P., Kim J.J., French K., and Goldie S.J. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 suppl 3 (2006) S178-S186
10. Dasbach E.J., Elbasha E.H., and Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28 (2006) 88-100
11. Kim J.J., Kuntz K.M., Stout N.K., et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166 (2007) 137-150
12. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 (2007) 28-41
13. Van de Velde N., Brisson M., and Boily M.C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 165 (2007) 762-775
14. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 (2006) 624-632
15. Llamazares M., and Smith? R. Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination?. BMC Public Health 8 (2008) 114
16. Basu S., Chapman G., and Galvani A. Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets. Proc Natl Acad Sci USA 104 (2008) 19018-19023
17. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 (2004) 1915-1923
18. Goldie S.J., Kohli M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 (2004) 604-615
19. Moscicki A.B., Schiffman M., Kjaer S., and Villa L.L. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 24 suppl 3 (2006) S42-S51
20. Goldhaber-Fiebert JD, Kim JJ, Kuntz KM, et al. Calibrating a complex microsimulation model of human papillomavirus and cervical cancer to multiple data sources. 28th Annual Meeting of the Society for Medical Decision Making; Boston, MA, USA; Oct 15-18, 2006.
21. May R.M. Uses and abuses of mathematics in biology. Science 303 (2004) 790-793
22. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 297 (2006) 813-819
23. Koutsky L.A., and Harper D.M. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine 24 suppl 3 (2006) S114-S121
24. Sanjose S., Diaz M., Castellsague X., et al. Worldwide prevalence and genotype distribution of cervical human papillmavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7 (2007) 453-459
25. Insinga R.P., Dasbach E.J., Elbasha E.H., Liaw K.L., and Barr E. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2 (2007) 15
26. Insinga R.P., Glass A.G., and Rush B.B. Pap screening in a US health plan. Cancer Epidemiol Biomarkers Prev 13 (2004) 355-360
27. GAVI Alliance. Which vaccines to invest in and when GAVI's strategic approach (2009), GAVI Alliance, Geneva. http://www.gavialliance.org/vision/strategy/vaccine_investment/index.php (accessed Dec 9, 2009).
28. Clifford G.M., Smith J.S., and Plummer M. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 (2003) 63-73
29. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191 suppl 1 (2005) S97-S106
30. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., and Roteli-Martins C.M. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
31. De Carvalho N, Roteli-Martins C, Teixeira J, Naud P, De Borba P, Zahaf T. Immunogenicity and safety of HPV-16/18 AS04-adjuvanted vaccine up to 7·3y. 25th International Papillomavirus Conference; Malmo, Sweden; May 8-14, 2009.
32. Sauvageau C., Duval B., Gilca V., Lavoie F., and Ouakki M. Human papillomavirus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 7 (2007) 304